Prediction of treatment outcome in NSCLC


David Oubre, M.D., Ph.D., medical oncologist and founder of Pontchartrain Cancer Center in Louisiana, says the results of the INSIGHT study (NCT03289780) test biomarkers in patients with non-small cell lung cancer (NSCLC) We show how it can predict treatment outcome.

In the INSIGHT study, blood-based host immune classifier (HIC) proteomic testing was performed in patients with NSCLC, and patients with HIC common cold tumors, who often do poorly when treated with monotherapy, nevertheless performed well. turned out to be bad. of their PD-L1 expression. Additionally, patients with HIC hot tumors had more favorable outcomes, even though the median overall survival (OS) in the study was not reached.

In the INSIGHT trial, HIC results were independent of PD-L1 and HIC was associated with immune checkpoint inhibitors (ICIs) in a subgroup of patients with PD-L1 expression ≥50% and ECOG performance status 0 or 1. ) monotherapy and not ICI with chemotherapy. Overall, median OS in patients with HIC-high tumors (95% CI, 15.4-undefined months) was not achieved, but in HIC cold patients (HR=0.38; 95%) at 5 months ( 95% CI, CI 0.27-0.53 compared with 2.9-6.4), P. < 0.0001). However, his median OS in patients receiving ICI monotherapy was 16.8 months compared to 2.8 months in patients not receiving monotherapy (HR = 0.36; 95 %CI, 0.22–0.58, P. < 0.0001).

In an interview with Targeted OncologyTMsOubre explained that while the study didn’t pinpoint mutations in patients’ disease, a comprehensive biomarker-driven lung cancer test could help us better understand the kinds of treatments patients need. For example, doing these tests can help determine how long a patient’s OS will be on monotherapy, but if the biomarkers were captured by: ALK1 Clinicians can then narrow down which treatments are most effective.

Transcription:

0:08 | This study showed that the test can also predict response to immunotherapy. What we got was whether the host’s immune factor levels were hot or cold.If the patient had her HIC hot, the average survival rate of a patient receiving immunotherapy was achieved in this study. It was not.I [believe] That 15.4 months was the lowest [in this case].

0:50 |

We knew it would take at least 15.4 months, but we didn’t reach that number [in patients that were considered HIC hot]In contrast, patients with HIC colds had a median survival of 5 months. There is almost a year difference between HIC Hot and her HIC Cold patient. This was highly predictive of the eventual survival of these patients.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *